Subsequently, we conducted an exploratory subgroup analysis to evaluate the association of several clinical variables (including performance status, number of previous line of treatments, tumor burden, resection of primary tumor, primary tumor sidedness, location of metastatic sites, and carcinoembryonic antigen) with treatment outcomes (eFigure 1 and eFigure 2 in Supplement 2). This evidence concerns the gene CEACAM5 and neoplasm.